Ranibizumab: all 350 studies that test it
Page 3 of 4. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.
- Combination Treatment of Intravitreal Ranibizumab, Focal/Grid Laser and Panretinal Photocoagulation in Patients With Diabetic Macula EdemaCompletedNCT02131350Phase 4
- Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF DosingWithdrawnNCT02127684Phase 2
- Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular DegenerationCompletedNCT02121353Phase 1/2
- Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVOStatus unknownNCT02091505Not applicable
- Analysis of Aqueous and Vitreous HumorStatus unknownNCT02067013Phase 2
- Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular DegenerationCompletedNCT02060604Phase 4
- Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular EdemaWithdrawnNCT02055911Phase 4
- The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular EdemaCompletedNCT02050828Phase 2
- Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.CompletedNCT01972763Phase 1/2
- Ranibizumab Treatment for Retinal Vein OcclusionStatus unknownNCT01968616Not applicable
- Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic MyopiaCompletedNCT01968486Phase 1
- Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCTCompletedNCT01968239Phase 2
- Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular GlaucomaCompletedNCT01922154Phase 4
- Efficacy Study of Lucentis in the Treatment of RetinoblastomaStatus unknownNCT01899066Phase 2
- Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)CompletedNCT01863199Phase 4
- Ranibizumab For Persistent Diabetic Macular Edema After BevacizumabStatus unknownNCT01845844Phase 1/2
- Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration.CompletedNCT01831947Phase 4
- Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein OcclusionStatus unknownNCT01827722Phase 4
- Use of Intravitreal Ranibizumab in the Treatment of Vitreous HemorrhageStatus unknownNCT01824043Phase 4
- Intravitreal Injections of Ranibizumab With Deferred Laser Grid Laser Photocoagulation for Treatment of Diabetic Macular Edema With Visual ImpairmentCompletedNCT01823965Phase 2
- Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair VisionTerminatedNCT01795209Phase 4
- Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic RetinopathyCompletedNCT01746563Phase 1/2
- Genetic Polymorphisms in Ranibizumab Treatment in Wet Age-Related Macular Degeneration (AMD)Status unknownNCT01676506Not applicable
- Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of LucentisStatus unknownNCT01669447Phase 4
- Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis)CompletedNCT01638858Not applicable
- Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO)Status unknownNCT01635803Phase 2/3
- Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (BRDME)Status unknownNCT01635790Phase 2/3
- Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular DegenerationCompletedNCT01628354Phase 4
- The LIMO Study, Lucentis for Treatment of Uveitic Patients With Refractory Cystoid Macular OedemaCompletedNCT01564108Phase 2
- Iray for Vascularized Pigment Epithelial Detachment (VPED) Secondary to Age Related Macular DegenerationStatus unknownNCT01521819Not applicable
- FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular DegenerationCompletedNCT01500915Phase 4
- Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular EdemaStatus unknownNCT01487629Phase 2
- Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular DegenerationCompletedNCT01473251Not applicable
- Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF TherapyCompletedNCT01472510Phase 2
- Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab DosingCompletedNCT01453920Phase 4
- Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein OcclusionCompletedNCT01448018Phase 4
- PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)CompletedNCT01445899Phase 2
- Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)WithdrawnNCT01406639Phase 1
- Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein OcclusionCompletedNCT01377597Phase 3
- Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular GlaucomaCompletedNCT01370135Not applicable
- Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment OutcomesCompletedNCT01363570Not applicable
- Aqueous Humor Level of Cytokines in Polypoidal Choroidal Vasculopathy and Change of Cytokines After Photodynamic TherapyStatus unknownNCT01360151Not applicable
- High Dose Intravitreal Ranibizumab for Recalcitrant Radiation RetinopathyCompletedNCT01334879Phase 1
- Ranibizumab and the Risk of Arterial Thromboembolic EventsTerminatedNCT01319188Phase 4
- A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular EdemaCompletedNCT01315275Phase 4
- Ranibizumab in Diabetic Vitrectomy. A Prospective, Randomised Controlled Trial of Ranibizumab Pre-treatment in Diabetic Vitrectomy - a Pilot StudyCompletedNCT01306981Phase 4
- Ranibizumab "Treat and Extend" in Diabetic Macular EdmaCompletedNCT01297569Phase 4
- Ranibizumab Short- and Log-term Effects on Retinal Function in wAMDCompletedNCT01269151Not applicable
- Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial TreatmentCompletedNCT01257815Phase 4
- Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab TherapyCompletedNCT01256632Not applicable
- Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis TherapyStatus unknownNCT01255774Phase 3
- Ranibizumab as a Rescue Therapy for Diabetic Macular EdemaWithdrawnNCT01253694Phase 2
- Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal VasculopathyStatus unknownNCT01248117Phase 1/2
- Ranibizumab for Myopic NeovascularizationStatus unknownNCT01246089Phase 4
- Treatment of Epiretinal Membranes With RanibizumabCompletedNCT01238393Not applicable
- Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment EvaluationCompletedNCT01223612Phase 4
- Genetics in Non-response to Anti-VEGF Treatment in Exudative AMDStatus unknownNCT01213667Phase 4
- Ranibizumab for Diabetic Traction Retinal DetachmentCompletedNCT01201161Phase 2
- Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO)Status unknownNCT01189526Phase 3
- HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular DegenerationTerminatedNCT01189019Phase 2
- Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent PterygiaCompletedNCT01169909Phase 1
- Comparison of Ranibizumab Monotherapy and Ranibizumab Combination Therapies in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular DegenerationCompletedNCT01162746Phase 2
- LUCAS (Lucentis Compared to Avastin Study)CompletedNCT01127360Phase 4
- Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein OcclusionStatus unknownNCT01123564Phase 2
- MIcrodoses of raNIbizumab in Diabetic MAcular Edema (MINIMA-2)CompletedNCT01112085Phase 2
- Panretinal Photocoagulation (PRP) Plus Ranibizumab for Proliferative Diabetic RetinopathyCompletedNCT01102946Phase 2
- Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized RegimenCompletedNCT01037348Phase 2
- Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage:CompletedNCT01030770Phase 2/3
- Lucentis for Macular Edema Associated With Central Retinal Vein OcclusionCompletedNCT01028248Phase 1
- Ranibizumab in Patients With Branch Retinal Vein OcclusionCompletedNCT01027481Phase 4
- Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid StreaksWithdrawnNCT01015495Phase 1/2
- Bevacizumab Versus Ranibizumab in Age Related Macular DegenerationStatus unknownNCT01014468Phase 3
- Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein OcclusionStatus unknownNCT01011374Phase 1
- Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)Status unknownNCT00993525Phase 1/2
- Intravitreal Ranibizumab in Retinal Pigment Epithelial DetachmentsCompletedNCT00976222Phase 4
- Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular DegenerationCompletedNCT00967213Phase 3
- Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis SyndromeStatus unknownNCT00955630Phase 1/2
- Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)CompletedNCT00942864Phase 3
- Safety and Efficacy of Intravitreal Ranibizumab as a Preoperative Adjunct Treatment Before Vitrectomy Surgery in Proliferative Diabetic Retinopathy (PDR) Compared to Vitrectomy AloneStatus unknownNCT00931125Phase 2
- Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of RanibizumabCompletedNCT00892398Not applicable
- Microperimetry and Optical Coherence Tomography (OCT) With Lucentis for Diabetic Macular Edema (DME)Status unknownNCT00885794Phase 2/3
- Study of Uveitic Macular Edema Treated With Ranibizumab or SteroidsWithdrawnNCT00846625Phase 2
- Lucentis to Treat Pigment Epithelial DetachmentCompletedNCT00841581Phase 2
- Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis EvaluationsCompletedNCT00831350Phase 2
- Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) PatientsCompletedNCT00826371Phase 3
- Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular DegenerationStatus unknownNCT00813891Phase 4
- Treatment Of Radiation Retinopathy TrialStatus unknownNCT00811200Phase 2/3
- A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMDCompletedNCT00793923Phase 1/2
- Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant SurgeryCompletedNCT00769145Phase 1
- Ranibizumab for the Inhibition of Neovascularization in PterygiaCompletedNCT00768963Phase 1
- Ranibizumab in Combination With Proton Beam Irradiation for Choroidal MelanomaCompletedNCT00765921Phase 1
- Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal MelanomaCompletedNCT00750399Phase 1
- Ranibizumab for Treating Submacular Vascularized Pigment Epithelial DetachmentsCompletedNCT00749021Phase 1
- Lucentis for New Onset Neovascular GlaucomaWithdrawnNCT00727038Phase 1/2
- Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD)WithdrawnNCT00726973Not applicable
- Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular DegenerationWithdrawnNCT00726466Phase 1
- Manta Study: Avastin Versus Lucentis in Age Related Macular DegenerationStatus unknownNCT00710229Phase 3
- Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel GrowthCompletedNCT00685854Phase 1
- Ranibizumab Injections to Treat Macular Telangiectasia With New Blood Vessel GrowthCompletedNCT00685503Phase 1
- Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based RetreatmentCompletedNCT00680498Phase 4